Mirum Pharmaceuticals Set to Unveil Volixibat Trial Results in Primary Sclerosing Cholangitis
Event summary
- Mirum Pharmaceuticals will host an investor call on May 4, 2026, to share topline results from the VISTAS study of volixibat in primary sclerosing cholangitis (PSC).
- Volixibat is an IBAT inhibitor in late-stage development for PSC and primary biliary cholangitis (PBC).
- Mirum's commercial portfolio includes LIVMARLI®, CHOLBAM®, and CTEXLI®, with a pipeline focused on rare diseases.
The big picture
Mirum Pharmaceuticals is poised to reveal critical data on volixibat, a key asset in its pipeline targeting PSC. The results could significantly influence the company's strategic positioning in the rare disease market, particularly as it competes with other biotech firms developing therapies for cholestatic liver diseases. The outcome may also impact investor confidence and potential partnerships or acquisitions in the space.
What we're watching
- Clinical Efficacy
- How the topline results from the VISTAS study will impact the perceived efficacy and market potential of volixibat in treating PSC.
- Regulatory Pathway
- Whether positive results could accelerate the regulatory approval process for volixibat in PSC and PBC.
- Competitive Positioning
- The pace at which Mirum can differentiate volixibat from existing treatments in the rare disease space.
Related topics